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atients treated  with  tigecycline
years.ear Editor,
he  US Food and Drug Administration (FDA) have issued a
arning  describing increased mortality risk associated with
he  use of tigecycline when compared to other drugs in the
reatment  of serious infections. Such increased risk was  deter-
ined  using a pooled analysis of randomized clinical trials
hich  involved predominantly patients treated for ventilator-
ssociated pneumonia (VAP).1
In the present observational and retrospective study, we
etermined the mortality predictor factors between survivors
nd  nonsurvivors patients treated with tigecycline. Patients
ere  enrolled in the study at 23 Latin American centers
etween February 2006 and June 2009. Data collection from
linical  records was  done using an electronic form (LatinUser®
ebsite; http://www.clinicalrec.com.ar). Two tailed hypothesis
esting for difference in proportions and multivariable logis-
ic  regression to identify predictors of mortality were used for
nalysis.
Of  the 301 eligible patients, 208 patients were male and
he  mean age was  49.7 (range 18–86). The overall in-hospital
ortality was  36.5% (110/301 nonsurvivors vs 191/301 sur-
ivors).  Univariate analysis showed that age, hospitalization
n  intensive care unit, APACHE II score, VAP, microbiological
ocumentation, previous use of carbapenems and, immuno-
ompromise were  signiﬁcantly associated with mortality. The
ultivariate  analysis showed that only age [odds ratio (OR):
.026;  [95% CI 1–1.05], p = 0.0202]; VAP (OR: 2.757; [95% CI
.13–6.69], p = 0.0255) and APACHE II score (OR: 1.228; [95% CI
.10–1.23],  p = 0.0000) were identiﬁed as independent risk fac-
ors  for mortality (Table 1).
In concordance with the FDA warning, our study shows that
n-hospital  mortality with tigecycline was  signiﬁcantly higher
n  critically ill patients with VAP. Undoubtedly, from a strictly
cientiﬁc  point of view, there is no evidence to support tigecy-
line  use in these patients. In that sense, Freire et al. reported
igniﬁcantly lower cure rates in clinically evaluable patients
ith  VAP treated with tigecycline (47.9%) when compared to
mipenem (70.1%) (−22.2% [95% CI lower limit, −39.5%]). Basedon  these results, tigecycline has not been approved by the FDA
for  the treatment of VAP.2
Considering the attainable extracellular epithelial lining
ﬂuid  concentrations of tigecycline (0.37 g/mL), the cur-
rent  dosage of 50 mg  of tigecycline twice daily is probably
underdosed for the treatment of VAP caused by typi-
cal,  extracellular-acting bacteria such as Acinetobacter spp
(MIC90 ∼ 1 g/mL).3
Regardless of these issues, the tigecycline pharmacological
and microbiological proﬁles encourage physicians to use the
drug  for VAP due to multidrug-resistant (MDR)-pathogens. In
that respect, we have published that more  than 50% of the tige-
cycline  prescriptions in Argentina were for VAP, mainly due to
MDR-Acinetobacter spp.4 This practice is justiﬁed by the high
regional  resistance rates of MDR-pathogens with limited ther-
apeutic  options (e.g. carbapenem-resistant Acinetobacter spp.;
KPC-producing Enterobacteriaceae).
We  know that clinical trials are indispensable tools to gen-
erate  new knowledge and to test therapeutic options for the
care  mainly of critically ill patients, however, the epidemio-
logical situation usually force physicians to incorporate the
off-label  use of some antibiotics as part of their daily practice
(e.g.  polymyxins, fosfomycin, sulbactam and other antibiotics,
alone  or in combinations).
In  the speciﬁc case of tigecycline it is mandatory to con-
duct  clinical trials to generate comparative evidence about
tigecycline efﬁcacy and safety in VAP using higher doses (i.e.
200  mg initial and 100-q12), as well as to determine the role
of  tigecycline combinations with other antibiotics (carbapen-
ems,  polymyxins, and fosfomycin among others).
Observational studies although helpful, are generally not
adequate  to address these issues, and controlled clinical tri-
als  will be necessary to provide sufﬁcient and reliable evidence
to  support approval for new tigecycline indications and dos-
ing  schedules. Nevertheless, this process usually takes severalFor  the treatment of serious or life-threatening illness, FDA
regulations, issued in 1992, allow for “accelerated approval”
of  a drug or biologic product that provides a “meaningful
278  b r a z j i n f e c t d i s . 2 0 1 3;1 7(2):277–278
Table 1 – Multivariate analysis of factors associated with mortality in patients treated with tigecycline.
Survivors (n = 191) Non-survivors (n = 110) p OR
Age (mean) 47.31 SD 18.6 (18–86) 52.22 SD 21.4 (18–85) 0.0202 1.026 (95% CI, 1–1.05)
VAP (n; %) 98 (51) 74 (67) 0.0255 2.757 (95% CI, 1.13–6.69)
APACHE II (median) 11.45 SD 8.45 (0–27) 23.956 SD 13.1 (0–55) 0.0000 1.228 (95% CI, 1.10–1.23)
r
1
2
3
4
5VAP, ventilator associated pneumonia.
therapeutic beneﬁt. over existing treatments”.5 Assuming the
serious  infections due to MDR-pathogens as a considerable
unmet medical need, this type of programs  may  help to get
new  scientiﬁc evidence of tigecycline in a shorter time in order
to  improve our patients’ clinical outcome.
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